Status:

COMPLETED

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Lead Sponsor:

Hadassah Medical Organization

Conditions:

Major Depressive Disorder

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

In this project we aim to further refine indications for the use of the thyroid hormone - T3 for patients suffering from depression. We aim to identify a sub-group of patients who are more likely to r...

Detailed Description

The lifetime risk for major depressive disorder (MDD) is 15% in the general population. Current treatment approaches emphasize the achievement of remission. Remission implies virtual absence of depres...

Eligibility Criteria

Inclusion

  • Diagnosis of Major Depressive Episode (MDE) in the context MDD according to DSM-IV criteria, without psychotic features.
  • Hamilton Depression Scale (21 items, HAM-D) total \>16 with item 1 (depressed mood) \>2.
  • Age 18-70 years.
  • Male or female.
  • Competent and willing to give written informed consent.

Exclusion

  • Clinical hyper- or hypothyroidism or any other thyroid illness.
  • Neurological or other medical illness that may impact upon the study or limit prescription of the study medications.
  • Significant suicidal risk \[HAM-D item 3 (suicide) \>2\].
  • Comorbidity with any Psychotic Disorder, Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Eating Disorder.
  • Lifetime history of substance or alcohol dependence or of abuse in the preceding 12 months.
  • Treatment with the antidepressant, sertraline, in current episode.
  • More then one antidepressant trial or any augmentation treatment during current episode.
  • Length of current episode \>12 months
  • Female subjects pregnant or lactating or not using adequate contraception.

Key Trial Info

Start Date :

September 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2011

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT00421369

Start Date

September 1 2007

End Date

August 1 2011

Last Update

March 22 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hadassah Medical Organization

Jerusalem, Israel

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. | DecenTrialz